Ginkgo Bioworks Inc. (DNA)
Ginkgo Bioworks Statistics
Share Statistics
Ginkgo Bioworks has 57.48M shares outstanding. The number of shares has increased by -97.33% in one year.
| Shares Outstanding | 57.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 3.43% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.40M |
| Failed to Deliver (FTD) Shares | 14.76K |
| FTD / Avg. Volume | 1.05% |
Short Selling Information
The latest short interest is 7.83M, so 13.62% of the outstanding shares have been sold short.
| Short Interest | 7.83M |
| Short % of Shares Out | 13.62% |
| Short % of Float | 16.87% |
| Short Ratio (days to cover) | 5.41 |
Valuation Ratios
The PE ratio is -3.68 and the forward PE ratio is -1.54.
| PE Ratio | -3.68 |
| Forward PE | -1.54 |
| PS Ratio | 13.07 |
| Forward PS | 3.4 |
| PB Ratio | 3 |
| P/FCF Ratio | -9.77 |
| PEG Ratio | n/a |
Enterprise Valuation
Ginkgo Bioworks Inc. has an Enterprise Value (EV) of 2.58B.
| EV / Earnings | -2.89 |
| EV / Sales | 10.26 |
| EV / EBITDA | -3.14 |
| EV / EBIT | -2.98 |
| EV / FCF | -7.67 |
Financial Position
The company has a current ratio of 6.11, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.11 |
| Quick Ratio | 6.11 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 18.06 |
| Cash Flow / Debt | -1.22 |
| Interest Coverage | -9294.69 |
Financial Efficiency
Return on equity (ROE) is -0.81% and return on capital (ROIC) is -64.55%.
| Return on Equity (ROE) | -0.81% |
| Return on Assets (ROA) | -0.54% |
| Return on Capital (ROIC) | -64.55% |
| Revenue Per Employee | 206.45K |
| Profits Per Employee | -733.06K |
| Employee Count | 1.22K |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.17K |
Taxes
| Income Tax | -71.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -72.19% in the last 52 weeks. The beta is 1.1, so Ginkgo Bioworks 's price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | -72.19% |
| 50-Day Moving Average | 10.31 |
| 200-Day Moving Average | 13.9 |
| Relative Strength Index (RSI) | 64.96 |
| Average Volume (20 Days) | 1.40M |
Income Statement
In the last 12 months, Ginkgo Bioworks had revenue of 251.46M and earned -892.87M in profits. Earnings per share was -18.37.
| Revenue | 251.46M |
| Gross Profit | 197.45M |
| Operating Income | -864.41M |
| Net Income | -892.87M |
| EBITDA | -821.29M |
| EBIT | -864.41M |
| Earnings Per Share (EPS) | -18.37 |
Balance Sheet
The company has 944.07M in cash and 241.77M in debt, giving a net cash position of 702.30M.
| Cash & Cash Equivalents | 944.07M |
| Total Debt | 241.77M |
| Net Cash | 702.30M |
| Retained Earnings | -5.29B |
| Total Assets | 1.48B |
| Working Capital | 548.05M |
Cash Flow
In the last 12 months, operating cash flow was -295.50M and capital expenditures -40.80M, giving a free cash flow of -336.30M.
| Operating Cash Flow | -295.50M |
| Capital Expenditures | -40.80M |
| Free Cash Flow | -336.30M |
| FCF Per Share | -6.92 |
Margins
Gross margin is 78.52%, with operating and profit margins of -343.76% and -355.08%.
| Gross Margin | 78.52% |
| Operating Margin | -343.76% |
| Pretax Margin | -355.11% |
| Profit Margin | -355.08% |
| EBITDA Margin | -326.62% |
| EBIT Margin | -343.76% |
| FCF Margin | -133.74% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -128.01% |
| FCF Yield | -40.79% |
Analyst Forecast
The average price target for DNA is $10, which is -30.3% lower than the current price. The consensus rating is "Sell".
| Price Target | $10 |
| Price Target Difference | -30.3% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -5.69 |
| Piotroski F-Score | 3 |